William Dean Carlson, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Morphogenetic Proteins | 4 | 2017 | 844 | 0.610 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 750 | 0.400 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1351 | 0.310 |
Why?
|
| Bone Morphogenetic Protein Receptors | 2 | 2017 | 46 | 0.230 |
Why?
|
| Renin | 10 | 1994 | 647 | 0.200 |
Why?
|
| Bone Morphogenetic Protein 7 | 3 | 2017 | 110 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 3 | 2012 | 1996 | 0.150 |
Why?
|
| Heptanoic Acids | 3 | 2005 | 344 | 0.140 |
Why?
|
| Activin Receptors | 1 | 2017 | 40 | 0.140 |
Why?
|
| Activin Receptors, Type I | 1 | 2017 | 133 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2017 | 23597 | 0.110 |
Why?
|
| Peptides | 4 | 2017 | 4331 | 0.110 |
Why?
|
| Pyrroles | 3 | 2005 | 1119 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2017 | 615 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 1996 | 1210 | 0.100 |
Why?
|
| Smad3 Protein | 1 | 2012 | 165 | 0.090 |
Why?
|
| Proteins | 2 | 1996 | 5994 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2017 | 1726 | 0.080 |
Why?
|
| Myocardial Ischemia | 3 | 2005 | 2132 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 3749 | 0.080 |
Why?
|
| Antioxidants | 2 | 2005 | 1671 | 0.070 |
Why?
|
| Epitopes | 7 | 1988 | 2523 | 0.060 |
Why?
|
| Ascorbic Acid | 2 | 2005 | 657 | 0.060 |
Why?
|
| Apoptosis | 2 | 2017 | 9505 | 0.050 |
Why?
|
| Vitamin E | 2 | 2005 | 872 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2011 | 1735 | 0.050 |
Why?
|
| Regeneration | 1 | 2012 | 1516 | 0.050 |
Why?
|
| Crystallography | 2 | 1996 | 110 | 0.050 |
Why?
|
| Angina Pectoris | 2 | 2005 | 957 | 0.050 |
Why?
|
| Lovastatin | 1 | 2002 | 114 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2011 | 5126 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10426 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 2136 | 0.040 |
Why?
|
| Oligopeptides | 3 | 1994 | 1193 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 17060 | 0.040 |
Why?
|
| Kidney | 2 | 2012 | 7073 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2002 | 609 | 0.040 |
Why?
|
| Cholesterol, LDL | 2 | 2004 | 2395 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2004 | 970 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2005 | 1893 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 2 | 1987 | 308 | 0.030 |
Why?
|
| Terfenadine | 1 | 1995 | 15 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 6491 | 0.030 |
Why?
|
| Protein Conformation | 9 | 1988 | 3945 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 289 | 0.030 |
Why?
|
| Histamine H1 Antagonists | 1 | 1995 | 100 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 1995 | 143 | 0.030 |
Why?
|
| Crystallization | 1 | 1994 | 518 | 0.030 |
Why?
|
| Endopeptidases | 2 | 1987 | 760 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2012 | 97 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2012 | 72 | 0.020 |
Why?
|
| Captopril | 1 | 2012 | 261 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1994 | 844 | 0.020 |
Why?
|
| Structure-Activity Relationship | 3 | 2012 | 3049 | 0.020 |
Why?
|
| Models, Molecular | 4 | 1996 | 5377 | 0.020 |
Why?
|
| Peptide Library | 1 | 2012 | 351 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 3851 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 1994 | 1944 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2012 | 453 | 0.020 |
Why?
|
| X-Ray Diffraction | 2 | 1987 | 413 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 21069 | 0.020 |
Why?
|
| Heparin | 1 | 1996 | 1632 | 0.020 |
Why?
|
| Muramidase | 2 | 1987 | 163 | 0.020 |
Why?
|
| Hemerythrin | 1 | 1987 | 5 | 0.020 |
Why?
|
| Erythrocruorins | 1 | 1987 | 1 | 0.020 |
Why?
|
| Ultrasonography | 3 | 2011 | 5987 | 0.020 |
Why?
|
| Metalloproteins | 1 | 1987 | 98 | 0.020 |
Why?
|
| Hemeproteins | 1 | 1987 | 61 | 0.020 |
Why?
|
| Heart Failure | 1 | 2011 | 11837 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 568 | 0.020 |
Why?
|
| Humans | 20 | 2017 | 765926 | 0.020 |
Why?
|
| Antibodies | 3 | 1988 | 2415 | 0.020 |
Why?
|
| Antigens | 2 | 1987 | 1437 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 2255 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17596 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 1513 | 0.010 |
Why?
|
| Vaccines, Synthetic | 1 | 1987 | 622 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2012 | 968 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 12405 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1987 | 607 | 0.010 |
Why?
|
| Fibrosis | 1 | 2012 | 2073 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2005 | 208 | 0.010 |
Why?
|
| Female | 7 | 2017 | 396141 | 0.010 |
Why?
|
| Amniotic Fluid | 1 | 1986 | 381 | 0.010 |
Why?
|
| Diet Therapy | 1 | 2005 | 149 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 1987 | 900 | 0.010 |
Why?
|
| Brachial Artery | 1 | 2004 | 374 | 0.010 |
Why?
|
| Length of Stay | 1 | 1996 | 6486 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2005 | 643 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1995 | 6409 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 10727 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1987 | 1531 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6503 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2012 | 8107 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 1479 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2011 | 2778 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1996 | 4856 | 0.010 |
Why?
|
| Vasodilation | 1 | 2004 | 969 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 1987 | 9239 | 0.010 |
Why?
|
| Binding Sites | 2 | 1987 | 5999 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 2004 | 12417 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1994 | 8530 | 0.010 |
Why?
|
| Rats | 2 | 2012 | 23708 | 0.010 |
Why?
|
| Exercise Test | 1 | 2005 | 2185 | 0.010 |
Why?
|
| Amino Acid Sequence | 5 | 1988 | 13398 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2011 | 9351 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 1988 | 3801 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 1813 | 0.010 |
Why?
|
| Partial Thromboplastin Time | 1 | 1996 | 203 | 0.010 |
Why?
|
| Erythromycin | 1 | 1995 | 114 | 0.010 |
Why?
|
| Self Administration | 1 | 1996 | 386 | 0.010 |
Why?
|
| Triglycerides | 1 | 2002 | 2440 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1996 | 682 | 0.010 |
Why?
|
| Lipids | 1 | 2005 | 3317 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 1996 | 494 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2011 | 65194 | 0.010 |
Why?
|
| Cost Control | 1 | 1996 | 625 | 0.010 |
Why?
|
| Middle Aged | 6 | 2011 | 223016 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 655 | 0.010 |
Why?
|
| Boston | 2 | 1996 | 9334 | 0.010 |
Why?
|
| Urine | 1 | 1994 | 363 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 1995 | 655 | 0.010 |
Why?
|
| Syncope | 1 | 1995 | 431 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 10843 | 0.010 |
Why?
|
| Aged | 4 | 2011 | 171163 | 0.010 |
Why?
|
| Ribonucleotides | 1 | 1972 | 114 | 0.010 |
Why?
|
| Myoglobin | 2 | 1987 | 157 | 0.010 |
Why?
|
| Rabbits | 2 | 1987 | 4729 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1972 | 265 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 1156 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 2227 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 1416 | 0.010 |
Why?
|
| Animals | 7 | 2012 | 168735 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3249 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1996 | 1435 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 13463 | 0.010 |
Why?
|
| Aldosterone | 1 | 1994 | 881 | 0.000 |
Why?
|
| Pigments, Biological | 1 | 1987 | 52 | 0.000 |
Why?
|
| Rhizopus | 1 | 1987 | 22 | 0.000 |
Why?
|
| Leghemoglobin | 1 | 1987 | 2 | 0.000 |
Why?
|
| Immune Sera | 1 | 1988 | 601 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2004 | 59496 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 4851 | 0.000 |
Why?
|
| Follow-Up Studies | 2 | 2002 | 39228 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 860 | 0.000 |
Why?
|
| Peptide Mapping | 1 | 1987 | 259 | 0.000 |
Why?
|
| Chymotrypsin | 1 | 1987 | 136 | 0.000 |
Why?
|
| Chemistry | 1 | 1987 | 325 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1987 | 483 | 0.000 |
Why?
|
| Warfarin | 1 | 1996 | 1494 | 0.000 |
Why?
|
| Administration, Oral | 1 | 1995 | 4016 | 0.000 |
Why?
|
| Mice | 2 | 2012 | 81782 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2011 | 54807 | 0.000 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1995 | 1568 | 0.000 |
Why?
|
| Chymosin | 1 | 1986 | 2 | 0.000 |
Why?
|
| Reference Values | 1 | 1994 | 4909 | 0.000 |
Why?
|
| Trypsin | 1 | 1987 | 487 | 0.000 |
Why?
|
| Chromatography | 1 | 1986 | 187 | 0.000 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1986 | 205 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2077 | 0.000 |
Why?
|
| Enzyme Precursors | 1 | 1986 | 164 | 0.000 |
Why?
|
| Histidine | 1 | 1987 | 301 | 0.000 |
Why?
|
| Immunologic Techniques | 1 | 1986 | 212 | 0.000 |
Why?
|
| Computer Graphics | 1 | 1987 | 343 | 0.000 |
Why?
|
| Tryptophan | 1 | 1987 | 483 | 0.000 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6544 | 0.000 |
Why?
|
| Adult | 4 | 2004 | 223088 | 0.000 |
Why?
|
| Male | 5 | 2005 | 363815 | 0.000 |
Why?
|
| Computer Simulation | 2 | 1988 | 6251 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1987 | 747 | 0.000 |
Why?
|
| Immunization | 1 | 1988 | 1218 | 0.000 |
Why?
|
| Heart Rate | 1 | 1995 | 4203 | 0.000 |
Why?
|
| Patient Satisfaction | 1 | 1996 | 3477 | 0.000 |
Why?
|
| Immunoassay | 1 | 1987 | 742 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1987 | 1392 | 0.000 |
Why?
|
| Homeostasis | 1 | 1994 | 3338 | 0.000 |
Why?
|
| Patient Discharge | 1 | 1996 | 3460 | 0.000 |
Why?
|
| Dogs | 1 | 1987 | 3824 | 0.000 |
Why?
|
| Drug Design | 1 | 1987 | 1039 | 0.000 |
Why?
|
| Amino Acids | 1 | 1987 | 1709 | 0.000 |
Why?
|
| Adolescent | 2 | 2002 | 88811 | 0.000 |
Why?
|
| Time Factors | 1 | 2002 | 40097 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1996 | 22228 | 0.000 |
Why?
|
| Models, Theoretical | 1 | 1988 | 3560 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1987 | 4555 | 0.000 |
Why?
|
| Protein Binding | 1 | 1987 | 9296 | 0.000 |
Why?
|
| Cytosine Nucleotides | 1 | 1972 | 10 | 0.000 |
Why?
|
| Uracil Nucleotides | 1 | 1972 | 13 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1995 | 41680 | 0.000 |
Why?
|
| Adenine Nucleotides | 1 | 1972 | 111 | 0.000 |
Why?
|
| Models, Structural | 1 | 1972 | 338 | 0.000 |
Why?
|
| Models, Biological | 1 | 1987 | 9443 | 0.000 |
Why?
|
| Solvents | 1 | 1972 | 299 | 0.000 |
Why?
|
| Adenosine Monophosphate | 1 | 1972 | 232 | 0.000 |
Why?
|
| Thermodynamics | 1 | 1972 | 577 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1972 | 1430 | 0.000 |
Why?
|
| Risk Factors | 1 | 1995 | 74850 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1995 | 81537 | 0.000 |
Why?
|
| Mutation | 1 | 1987 | 30192 | 0.000 |
Why?
|